Guaiazulen
CAS 489-84-9
Guaiazulen (CAS 489-84-9) is a pharmaceutical compound with 2 bioactivity targets and 36 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 34025.336363636365 nM | 11 | - |
| - | AC50 | 1970.2 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Guaiazulen used for in pharmaceutical contexts?
Guaiazulen (CAS 489-84-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Guaiazulen?
Guaiazulen has 36 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Urinary tract infection, Aneurysm, Aneurysm ruptured, Cardiac failure, Chills. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Guaiazulen also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Guaiazulene with EU status "permitted".
What clinical phase is Guaiazulen in?
No phase 1-4 clinical development badge is rendered for Guaiazulen because the matched compound identifier rows do not contain a max-phase value.